Enliven Therapeutics: Lori Anne Kunkel exercises options

The two options had different vesting terms: the 3,741-share option was fully vested, while the 7,300-share option vested monthly subject to continued outside-director service.

Available on EDGAR 11/03/2026 - 05:21 PM EST Accepted by SEC EDGAR 11/03/2026 - 05:21 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Lori Anne Kunkel, a director of Enliven Therapeutics, Inc. (ELVN), exercised stock options on October 30, 2026, to acquire 3,741 and 7,300 common shares at exercise prices of $1.12 and $18.30 per share, respectively. The 3,741-share option was fully vested and exercisable as of that date. The 7,300-share option was originally for 37,882 shares and vests as to 1/36th of the shares on May 8, 2024, and each month thereafter, subject to her continuing as an outside director through each vesting date.

Insider Trade Summary

11,041 shares exercised/converted

Exercise 4 txns

Insider Kunkel Lori Anne

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1	3,741	$0.00	$0.00
Exercise	Stock Option (right to buy) F2	7,300	$0.00	$0.00
Exercise	Common Stock	3,741	$1.12	$4K
Exercise	Common Stock	7,300	$18.30	$134K

Holdings After Transaction: Stock Option (right to buy) — 30,582 contracts (Direct); Common Stock — 52,925 shares (Direct)

Footnotes (2)

1. F1. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
2. F2. The option, originally for 37,882 shares, of which 7,300 shares have been exercised, vests as to 1/36th of the shares on May 8, 2024 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

Key Figures

Common shares acquired through option exercise: 3,741 shares Exercise price: $1.12 per share Common shares acquired through option exercise: 7,300 shares +2 more

5 metrics

Common shares acquired through option exercise 3,741 shares October 30, 2026; exercise price $1.12 per share

Exercise price $1.12 per share Option exercise on October 30, 2026

Common shares acquired through option exercise 7,300 shares October 30, 2026; exercise price $18.30 per share

Exercise price $18.30 per share Option exercise on October 30, 2026

Original option size 37,882 shares Option described in the vesting footnote

Key Terms

fully vested and exercisable, vests as to 1/36th, outside director

3 terms

fully vested and exercisable technical

"All of the shares subject to this option are fully vested and exercisable"

vests as to 1/36th technical

"vests as to 1/36th of the shares on May 8, 2024"

outside director technical

"continuing as an outside director through each such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did Lori Anne Kunkel exercise for ELVN, and at what prices?

Lori Anne Kunkel exercised options to acquire 3,741 common shares at $1.12 per share and 7,300 common shares at $18.30 per share on October 30, 2026.

What were the vesting terms for Lori Anne Kunkel's ELVN options?

The option for 3,741 shares was fully vested and exercisable as of October 30, 2026. The other option was originally for 37,882 shares and vests as to 1/36th of the shares on May 8, 2024, and each month thereafter, subject to Kunkel continuing as an outside director through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunkel Lori Anne

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME CALIFORNIA 94010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2026		M		3,741	A	$1.12	45,625	D
Common Stock	10/30/2026		M		7,300	A	$18.3	52,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.12	10/30/2026		M			3,741	(1)	06/15/2030	Common Stock	3,741	$0	0	D
Stock Option (right to buy)	$18.3	10/30/2026		M			7,300	(2)	04/08/2034	Common Stock	7,300	$0	30,582	D

Explanation of Responses:

1. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

2. The option, originally for 37,882 shares, of which 7,300 shares have been exercised, vests as to 1/36th of the shares on May 8, 2024 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

	/s/ Ben Hohl, by power of attorney	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)